Wasatch Advisors LP Has $15.92 Million Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Wasatch Advisors LP lessened its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 17.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 708,377 shares of the company's stock after selling 149,690 shares during the quarter. Wasatch Advisors LP owned approximately 1.00% of Nurix Therapeutics worth $15,917,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Amalgamated Bank grew its position in Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company's stock valued at $49,000 after purchasing an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Nurix Therapeutics by 31.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company's stock valued at $54,000 after acquiring an additional 559 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Nurix Therapeutics by 299.8% in the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company's stock worth $95,000 after acquiring an additional 3,424 shares during the last quarter. International Assets Investment Management LLC increased its stake in shares of Nurix Therapeutics by 1,098.4% in the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company's stock worth $101,000 after acquiring an additional 4,119 shares during the last quarter. Finally, Quest Partners LLC raised its holdings in shares of Nurix Therapeutics by 21.3% during the third quarter. Quest Partners LLC now owns 7,458 shares of the company's stock worth $168,000 after acquiring an additional 1,312 shares in the last quarter.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 3,546 shares of the company's stock in a transaction on Friday, November 1st. The stock was sold at an average price of $24.28, for a total value of $86,096.88. Following the completion of the transaction, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $818,818.72. This represents a 9.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Christine Ring sold 3,290 shares of the firm's stock in a transaction on Monday, October 14th. The stock was sold at an average price of $25.00, for a total value of $82,250.00. Following the completion of the transaction, the insider now directly owns 24,592 shares of the company's stock, valued at approximately $614,800. This trade represents a 11.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,451 shares of company stock worth $663,160 in the last ninety days. 7.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on NRIX shares. Oppenheimer boosted their target price on Nurix Therapeutics from $27.00 to $30.00 and gave the company an "outperform" rating in a research note on Wednesday, September 4th. Jefferies Financial Group began coverage on Nurix Therapeutics in a research note on Friday, October 11th. They issued a "buy" rating and a $41.00 price target for the company. UBS Group began coverage on shares of Nurix Therapeutics in a research report on Thursday, October 24th. They set a "buy" rating and a $35.00 price objective on the stock. Needham & Company LLC reissued a "buy" rating and issued a $29.00 target price on shares of Nurix Therapeutics in a research report on Wednesday, November 6th. Finally, Robert W. Baird began coverage on shares of Nurix Therapeutics in a report on Friday, September 6th. They set an "outperform" rating and a $26.00 price target on the stock. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, Nurix Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $29.40.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX traded up $0.88 during trading hours on Friday, hitting $22.11. 378,726 shares of the company's stock were exchanged, compared to its average volume of 1,067,337. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -7.60 and a beta of 2.20. The company's 50-day moving average price is $24.02 and its 200-day moving average price is $21.84. Nurix Therapeutics, Inc. has a 1-year low of $5.95 and a 1-year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Friday, October 11th. The company reported ($0.67) EPS for the quarter, hitting analysts' consensus estimates of ($0.67). The company had revenue of $12.59 million during the quarter, compared to analyst estimates of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. On average, research analysts expect that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.